Why the Revenue lost its appeal on classifying calcium injections as medicines for cattle.

Two shots of calcium, one question for the Supreme Court: is it a medicine or a fluid?

When M/s. Denis Chem Lab Ltd. manufactured Calcium Borogluconate Injection and Calcium Magnesium Borogluconate Injection for use on cattle, they believed they were making intravenous fluids — eligible for excise duty exemption. The Commissioner of Central Excise, Ahmedabad II, disagreed. The Revenue argued that because these products contained boric acid and chlorocresol, and were used to treat animal diseases like milk fever and tetany, they were medicines. The stakes? Millions in excise duty, the classification of veterinary injectables, and a principle that would determine how tax authorities read exemption notifications. The Supreme Court of India, in a judgment authored by Justice B.V. Nagarathna and concurred by Justice Ujjal Bhuyan, finally settled the dispute on July 26, 2023.

What the Commissioner saw, and what CESTAT overturned

The story begins with the Commissioner of Central Excise, Ahmedabad II, who denied the benefit of excise duty exemption to Denis Chem Lab. The Commissioner held that the products were medicinal in nature — not intravenous fluids for replenishment. The company moved an appeal before the Customs, Excise and Service Tax Appellate Tribunal (CESTAT), West Zonal Bench, Ahmedabad. On October 13, 2008, CESTAT allowed the appeal, holding that Notification No.3/2001 was clarificatory of Notification No.6/2000. The Tribunal relied on a letter from the Deputy Drug Controller confirming that the products were intravenous fluids containing electrolytes. The Revenue, dissatisfied, approached the Supreme Court.

The exemption notifications at the heart of the fight

The dispute turned on two Central Excise notifications issued under the Central Excise Act, 1944. Notification No.6/2000-C.E. dated March 1, 2000, at Serial No.47-A under Chapter Heading No.30, and Notification No.3/2001-C.E. dated March 1, 2001. The latter exempted "Intravenous Fluids, which are used for sugar, electrolyte or fluid replenishment." The Revenue argued that the products did not fall within this description because they contained boric acid and chlorocresol — chemicals that, according to the Revenue, transformed them into medicines for treating specific veterinary diseases.

What the Revenue argued, and what the company countered

The learned Counsel for the Revenue contended that the addition of boric acid and chlorocresol rendered the products medicinal. They cited CCE & Customs v. Parenteral Drugs (I) Ltd., (2009) 14 SCC 342, where the Supreme Court had remanded a similar matter to CESTAT to consider the composition of the product and whether it was a Schedule 'H' drug. The Revenue argued that the present case should also be remanded for a fresh determination on the composition issue.

The learned Counsel for Denis Chem Lab countered that the products were predominantly composed of glucose (sugar) and electrolytes (minerals) meant for fluid and electrolyte replenishment. The boric acid and chlorocresol were present only in minimal proportions as preservatives — they did not alter the essential character of the product. The company argued that the composition test, not the end-use test, should govern classification.

Why the Supreme Court rejected the Revenue's appeal

The Supreme Court dismissed the Revenue's appeals. The Bench held that the composition of the product is the relevant test for determining whether it falls under the description of "Intravenous Fluids" for excise duty exemption. The Court observed that the products were predominantly composed of glucose and electrolytes. The addition of boric acid and chlorocresol in minimal proportions as preservatives did not change the essential character of the product. The Court distinguished Parenteral Drugs, noting that in that case the composition issue was specifically left open by the Supreme Court for CESTAT to decide — here, CESTAT had already examined the composition and found the products to be intravenous fluids.

THE TEST: To determine whether a product qualifies as an 'Intravenous Fluid' for excise duty exemption, apply the composition test — examine what the product predominantly consists of, not whether it is used to treat a particular disease. Minimal preservatives do not alter the essential character.

The doctrine that mattered: composition over end-use

The ratio decidendi in this case is straightforward but powerful. The Supreme Court held that to determine whether a product falls under the description of "Intravenous Fluids" for excise duty exemption, the relevant test is the composition of the product, not whether the product is used for treatment of any particular disease. The addition of chemicals like boric acid and chlorocresol in minimal proportions as preservatives does not alter the essential character of a product that predominantly consists of glucose (sugar) and electrolytes (minerals) meant for replenishment. It remains an intravenous fluid eligible for exemption.

The Court also made an obiter observation that the object and purpose of the grant of exemption for intravenous fluids is to ensure that these products are available at a reduced price and can be easily accessible for use on human beings or animals readily, as they are in the nature of life-saving products. This purposive construction could be invoked in future disputes about the scope of similar exemptions for essential or life-saving products.

Why this matters in practice

For advocates, CFOs, and founders dealing with excise duty or GST classification disputes, this judgment provides a clear rule: when a product's composition is predominantly one thing, and the disputed ingredients are merely preservatives or stabilizers, the composition test governs. The Revenue cannot reclassify a product as a medicine simply because it is used during the treatment of a disease. The product can be used both as a preventive measure and during the course of treatment — that dual-use characterization does not change its essential character.

For tax litigation strategists, the case also offers a lesson in how to use precedent. The Revenue cited Parenteral Drugs to argue for a remand. The Supreme Court distinguished it, noting that in Parenteral Drugs, the composition issue was specifically left open — here, CESTAT had already decided it. The takeaway: if you want a remand, you need to show that the lower tribunal did not examine the composition at all, not that it examined it and reached a conclusion you disagree with.

The bottom line

When the composition of a product is predominantly glucose and electrolytes, and the disputed ingredients are minimal preservatives, the product qualifies as an intravenous fluid for excise duty exemption — regardless of whether it is used to treat a specific disease.